Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16139759 | 0.78 | ALDH1A1 (0.53) | LMNAMAPTKDM4EMEN1GAA | |
| SCHEMBL17645912 | 0.77 | KDM4E (1.00) | LMNAMAPTKDM4EMEN1GAA | |
| SCHEMBL17645943 | 0.76 | MAPT (0.59) | LMNAMAPTKDM4EMEN1GAA | |
| Hydrochloric Acid SCHEMBL4676438 | 0.76 | ROCK1 (0.44) | LMNAMAPTKDM4EMEN1GAA | |
| SCHEMBL6951902 | 0.70 | LMNA (0.63) | LMNAMAPTKDM4EMEN1GAA | |
| SCHEMBL28176679 | 0.70 | CA2 (0.39) | LMNAMAPTKDM4EMEN1GAA | |
| SCHEMBL25211155 | 0.69 | HRH4 (0.37) | KDM4EGAAPIK3C3 | |
| SCHEMBL6951898 | 0.68 | ALDH1A1 (0.65) | LMNAMAPTKDM4EMEN1GAA | |
| SCHEMBL939122 | 0.67 | POLB (0.63) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL17645942 | 0.67 | LMNA (0.55) | LMNAMAPTKDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204007-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1 INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926315-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2017-08-17 | — | — | US | disclosed |
| EP-3204007-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Flatley Discovery Lab, LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573948-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057522-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472357-B2 | Triazolopyridine compounds and methods for the treatment of cystic fibrosis | CFTR, KCNJ11, KCNJ1 | LMNA 2788/4885MAPT 4870/4885KDM4E 4230/4885 |
| US-20170233388-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | LMNA 2788/4885MAPT 4870/4885KDM4E 4230/4885 |
| US-20160096835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, KCNJ11, KCNJ1 | LMNA 2788/4885MAPT 4870/4885KDM4E 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.